- Home
- HQI vs PBYI Comparison
HQI vs PBYI Comparison
Compare HQI & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- PBYI
- Stock Information
- Founded
- HQI 2002
- PBYI 2010
- Country
- HQI United States
- PBYI United States
- Employees
- HQI N/A
- PBYI N/A
- Industry
- HQI Professional Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- HQI Consumer Discretionary
- PBYI Health Care
- Exchange
- HQI Nasdaq
- PBYI Nasdaq
- Market Cap
- HQI 143.3M
- PBYI 167.3M
- IPO Year
- HQI N/A
- PBYI N/A
- Fundamental
- Price
- HQI $10.01
- PBYI $3.45
- Analyst Decision
- HQI Strong Buy
- PBYI Strong Buy
- Analyst Count
- HQI 2
- PBYI 1
- Target Price
- HQI $16.00
- PBYI $7.00
- AVG Volume (30 Days)
- HQI 12.4K
- PBYI 379.0K
- Earning Date
- HQI 08-07-2025
- PBYI 07-31-2025
- Dividend Yield
- HQI 2.35%
- PBYI N/A
- EPS Growth
- HQI N/A
- PBYI 143.51
- EPS
- HQI 0.24
- PBYI 0.77
- Revenue
- HQI $33,651,000.00
- PBYI $232,709,000.00
- Revenue This Year
- HQI N/A
- PBYI N/A
- Revenue Next Year
- HQI $4.99
- PBYI N/A
- P/E Ratio
- HQI $39.19
- PBYI $4.36
- Revenue Growth
- HQI N/A
- PBYI 2.68
- 52 Week Low
- HQI $9.04
- PBYI $2.23
- 52 Week High
- HQI $15.75
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- HQI 49.96
- PBYI 48.53
- Support Level
- HQI $9.78
- PBYI $3.25
- Resistance Level
- HQI $10.24
- PBYI $3.39
- Average True Range (ATR)
- HQI 0.23
- PBYI 0.15
- MACD
- HQI 0.02
- PBYI -0.03
- Stochastic Oscillator
- HQI 57.41
- PBYI 22.22
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.